NDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
DESFERAL (deferoxamine mesylate) by Gland Pharma is reactions. First approved in 1968.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESFERAL (deferoxamine mesylate) is an injectable iron chelator that binds ferric iron from ferritin and hemosiderin, facilitating urinary and fecal excretion. It is used to treat iron overload conditions in patients requiring chronic transfusions or suffering from hemochromatosis. The drug does not chelate iron from hemoglobin, cytochromes, or transferrin-bound iron.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation and transition planning for brand professionals.
Mechanism of Action
reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin. Deferoxamine mesylate does not cause any demonstrable increase in the excretion of electrolytes or trace metals. Theoretically, 100…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DESFERAL offers experience in a mature, niche therapeutic area with stable patient populations but limited growth trajectory. Career value lies in mastering specialty pharmacy dynamics, patient adherence strategies, and transition management as the product approaches generic competition.
Brand Manager
Worked on DESFERAL at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.